Overview

* Conmed ( CNMD ) Q2 sales rise 3.1% yr/yr, beating analyst expectations, per LSEG data

* Adjusted EPS for Q2 beats consensus, driven by supply chain improvements

* Company raises full-year revenue and adjusted EPS guidance

Outlook

* Based on current forex rates, Conmed ( CNMD ) expects headwinds to be immaterial vs 50-70 bps of headwind previously

* Conmed ( CNMD ) expects 2025 revenue between $1.356 bln and $1.378 bln

* Company projects full-year adjusted EPS of $4.40 to $4.55

* Foreign currency headwind estimated at 10 cents on EPS

* Tariffs expected to reduce EPS by $0.09 in H2 2025

Result Drivers

* SUPPLY CHAIN IMPROVEMENTS - Conmed ( CNMD ) attributes Q2 performance to strengthening supply chain operations, per CEO Patrick J. Beyer

* INTERNATIONAL GROWTH - International sales increased by 3.4% yr/yr, contributing to overall revenue growth

* PRODUCT MIX - Single-use products saw a 6.6% increase, partially offsetting a decline in capital products

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $342.34 $338.20

mln mln (6

Analysts

)

Q2 Beat $1.15 $1.12 (6

Adjusted Analysts

EPS )

Q2 EPS $0.69

Q2 Net $21.42

Income mln

Q2 $38.16

Income mln

from

Operatio

ns

Q2 $29.92

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Conmed Corp ( CNMD ) is $69.00, about 27.1% above its July 29 closing price of $50.29

* The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)